Compounds > raloxifene hydrochloride
Page last updated: 2024-08-23

raloxifene hydrochloride and fulvestrant

raloxifene hydrochloride has been researched along with fulvestrant in 90 studies

Research

Studies (90)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's13 (14.44)18.2507
2000's57 (63.33)29.6817
2010's20 (22.22)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bryant, HU; Cullinan, GJ; Glasebrook, AL; Hauser, KL; Muehl, BS; Palkowitz, AD; Pell, TR; Phillips, DL; Sato, M; Shetler, PK; Short, LL; Thrasher, KJ1
Harris, HA; Jirkovsky, I; Komm, BS; Miller, CP; Moran, RA; Tran, BD1
Fuchs-Young, R; Hale, L; Howe, S; Miles, R; Walker, C1
Gradishar, WJ; Jordan, VC1
Carver, JM; Lundeen, SG; McKean, ML; Winneker, RC1
Cheskis, BJ; Karathanasis, S; Lyttle, CR1
Logie, C; Nichols, M; Rientjes, JM; Stewart, AF1
Catherino, WH; Jordan, VC; Levenson, AS1
Belanger, A; Gauthier, S; Labrie, C; Labrie, F; Merand, Y; Poirier, D; Sanchez, R; Simard, J; Singh, SM1
Lane, MV; Merchenthaler, I; Shughrue, PJ1
Funder, JW; Logie, C; Myles, K; Nichols, M; Stewart, AF1
Jordan, VC; Liu, H; Schafer, JI; Tonetti, DA1
Evans, A; Healy, D; Vollenhoven, B1
Christensen, DJ; Fowlkes, DM; McDonnell, DP; Nagel, SC; Norris, JD; Paige, LA; Wijayaratne, AL1
Burakov, D; Cheskis, BJ; Freedman, LP; Rachez, C; Wong, CW1
Baker, VL; Jaffe, RB; Leitman, D1
Genazzani, AR; Simoncini, T1
Bentrem, DJ; Jordan, VC; Liu, H; MacGregor Schafer, J; Zapf, JW1
Bean, JS; Bensch, WR; Cox, DA; Cullinan, GJ; Fahey, KJ; Kauffman, RF1
Fisher, PW; Gowen, M; Nadeau, DP; Nuttall, ME; Stroup, GB; Suva, LJ1
Terakawa, N1
Diel, P; Michna, H; Olff, S; Schmidt, S2
Adachi, K; Hayakawa, J; Hisamoto, K; Kanda, Y; Mabuchi, S; Miyamoto, Y; Murata, Y; Nishio, Y; Ohmichi, M; Takahashi, K; Taniguchi, N; Tasaka, K1
Aguilar, E; Barreiro, ML; Gonzalez, LC; Pinilla, L; Tena-Sempere, M1
Chan, S1
Obrero, M; Shapiro, DJ; Yu, DV1
Kushner, PJ; Nguyen, P; Webb, P1
Bianco, NR; Montano, MM; Perry, G; Smith, MA; Templeton, DJ1
Abrams, J; Deighton-Collins, S; Koide, A; Koide, S; Martinez, A; Schwartz, JA; Skafar, DF; Zhao, C1
Eriksson, B; Eriksson, H; Muravitskaya, N; Sahlin, L; Stygar, D1
Arimoto-Ishida, E; Hisamoto, K; Kurachi, H; Mabuchi, S; Mori, A; Murata, Y; Ohmichi, M; Takahashi, K; Tasaka, K; Tsutsumi, S; Yoshida, M1
Eckhardt, S1
Amant, F; Joubert, A; Lindeque, BG; Lottering, ML; Thaver, V; Vergote, I1
Balaguer, P; Bonnet, S; Cavaillès, V; Duong, V; Escande, A; Margueron, R; Vignon, F1
Häyry, P; Kangas, L; Luoto, NM; Savolainen-Peltonen, H1
Chan, YC; Huang, Y; Lau, CW; Leung, FP; Vanhoutte, PM; Yao, X1
Allan, G; D'Andrea, MR; Guo, JZ; Haynes-Johnson, D; Lawrence, D; Lundeen, S; Pacia, E; Tynan, S1
Aoyagi, Y; Asao, T; Buzdar, AU; Hashimoto, A; Sato, K; Shibata, J; Terada, T; Wierzba, K; Yamamoto, Y; Yano, S; Yonekura, K1
Adelman, SJ; Elloso, MM; Harris, HA; Henderson, RA; Phiel, K1
Huuskonen, J; Nuutinen, T; Ojala, J; Salminen, A; Suuronen, T; Thornell, A1
Fischer, PA; Peekhaus, NT; Schneeweis, JE; Shi, X; Strulovici, B; Zheng, W1
Blok, LJ; Burger, CW; Gielen, SC; Hanifi-Moghaddam, P; Kühne, LC1
Ariazi, EA; Glidewell-Kenney, C; Ishikawa, T; Jameson, JL; Lee, EJ; Pillai, S; Weiss, J1
Dodwell, D; Johnston, S; Wardley, A1
Baker, RS; Clark, KE; Mershon, JL; Zoma, WD1
Ariazi, E; Bertucci, A; Grigg, R; Jordan, VC; Lee, ES; Meeke, K; Morris, C; O'Regan, RM; Osipo, C; Sarker, MA1
Clarke, R; Dai, P; Lou, MA; Lu, JF; Nazarov, V; Wong, LJ1
Ayala, GE; Hsieh, JT; Jian, W; Kim, IY; Lerner, SP; Shen, SS; Smith, CL; Sonpavde, G; Younes, M; Yu, J1
Glusa, E; Gust, R; Moritz, A; Pertz, HH; Radtke, OA1
Baetta, R; Bolego, C; Cignarella, A; Corsini, A; Gaion, RM; Pelosi, V; Pinna, C; Sanvito, P1
Birkenes, B; Dahm, AE; Iversen, N; Ree, AH; Sandset, PM1
He, H; Hu, Q; Liu, XX; Su, JX; Tu, B; Wang, X; Yang, FL; Zeng, XW1
Au, AL; Huang, Y; Kwan, YW; Leung, FP; Leung, HS; Seto, SW; Yao, X; Yung, LM1
Guo, SW; Olive, DL1
Asselin, E; Bélanger, G; Boucher, V; Déry, MC; Leblanc, K; Parent, S; Sexton, E1
Auger, A; Cotnoir-White, D; Dayan, G; Hébert, E; Hilmi, K; Jeyakumar, M; Katzenellenbogen, J; Loch, C; Lupien, M; Mader, S; Moras, D; Pinard, GA; Wurtz, JM1
Massheimer, V; Mendiberri, J; Polini, N; Rauschemberger, MB; Selles, J1
Chiu, SW; Huang, Y; Jin, MW; Lau, CP; Li, GR; Liu, H; Sun, HY; Xiang, JZ1
Altobelli, G; Biglia, N; Cicatiello, L; Cimino, D; De Bortoli, M; Friard, O; Fuso, L; Ponzone, R; Ravo, M; Scafoglio, C; Sismondi, P; Weisz, A1
Härkönen, PL; Hentunen, TA; Kangas, L; Michael, H; Väänänen, HK1
Huang, Y; Huang, YL; Lai, B; Yao, T; Zheng, P; Zhu, YC1
Au, CL; Huang, Y; Laher, I; Leung, FP; Leung, HS; Vanhoutte, PM; Yao, X; Yung, LM1
Bielawski, T; Miltyk, W; Palka, J; Surazynski, A; Wolczynski, S; Zbucka, M1
Collins, P; Krust, A; MacLeod, KT; Ullrich, ND1
Brentani, MM; Nagai, MA1
Casa, AJ; Cui, X; Dearth, RK; Lee, AV; Litzenburger, BC1
Akishita, M; Eto, M; Kozaki, K; Okabe, T; Ouchi, Y; Yu, J1
Davis, AM; Kohl, JA; Mao, J; Naz, B; Rosenfeld, CS1
Chung, SH; Lambert, PF1
Abe, Y; Irie, T; Iwasaki, N; Komatsu, M; Majima, T; Minami, A; Takahata, M1
Chan, YC; Chen, ZY; Huang, Y; Lau, CW; Leung, FP; Tian, XY; Tsang, SY; Wong, WT; Yao, X; Yung, LM1
Goldstein, RE; Klinge, CM; Kumar, A1
Ashcroft, FJ; Jones, ED; Mancini, MA; Mikic, I; Newberg, JY1
Belleau, P; Calvo, E; Labrie, F; Luu-The, V; Martel, C1
Hoffman, KL; Lerner, SP; Smith, CL1
Han, SJ; Liu, S; Smith, CL1
Crippa, V; Messi, E; Piccolella, M; Poletti, A; Tetel, MJ1
Andersson, A; Börjesson, AE; Carlsten, H; Farman, HH; Gustafsson, JÅ; Lagerquist, MK; Movérare-Skrtic, S; Ohlsson, C; Sjögren, K; Stubelius, A; Windahl, SH1
Bao, J; Chen, Y; Dai, Y; Hu, X; Li, R; Lu, Z; Qiu, W; Shu, Y; Wu, A; Xu, W1
Ishida, A; Ishihara, Y; Itoh, K; Yamazaki, T1
He, Y; Li, LH; Liu, Y; Tang, WR; Wu, ZB1
Hui, Y; Kurogi, K; Liu, MC; Luo, L; Sakakibara, Y; Suiko, M; Zhang, L; Zhou, C1
Cygankiewicz, AI; Jacenik, D; Krajewska, WM1
Komm, BS; Pickar, JH1
Cazzulino, AS; Denny, CA; Martinez, R; Tomm, NK1
Basile, I; Gallud, A; Garcia, M; Gary-Bobo, M; Maynadier, M1
Li, L; Li, LZ; Li, ZY; Sun, J; Sun, WJ; Wang, C; Wang, Y; Yu, LR; Zhang, YL; Zhao, Y1
Blanco-Vaca, F; Dávalos, A; Escolà-Gil, JC; Fernández-Suárez, ME; Gómez-Coronado, D; Lasunción, MA; Martínez-Botas, J; Pastor, O1
Brown, M; Buchwalter, G; Carlson, KE; Chandarlapaty, S; Dharmarajan, V; Fanning, SW; Fowler, CE; Greene, GL; Griffin, PR; Han, R; Hosfield, DJ; Houtman, R; Jeselsohn, R; Karimi, M; Katzenellenbogen, JA; Lainé, M; Martin, TA; Mayne, CG; Nettles, KW; Nowak, J; Nwachukwu, JC; Shen, Y; Tajkhorshid, E; Toy, W1

Reviews

12 review(s) available for raloxifene hydrochloride and fulvestrant

ArticleYear
Clinical potential of new antiestrogens.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:2

    Topics: Antineoplastic Agents, Hormonal; Bone Density; Drugs, Investigational; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene

1997
Modern antioestrogens and the coming revolution in women's health care.
    The Australian & New Zealand journal of obstetrics & gynaecology, 1999, Volume: 39, Issue:3

    Topics: Bone and Bones; Breast Neoplasms; Clomiphene; Estradiol; Estrogen Receptor Modulators; Estrogens, Non-Steroidal; Female; Fulvestrant; Genital Diseases, Female; Humans; Isoflavones; Osteoporosis; Phytoestrogens; Plant Preparations; Plants; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health

1999
Selective estrogen receptor modulators in reproductive medicine and biology.
    Obstetrical & gynecological survey, 2000, Volume: 55, Issue:7 Suppl 2

    Topics: Estradiol; Estrogen Replacement Therapy; Fulvestrant; Genistein; Humans; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen

2000
Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
    Oncology, 2000, Volume: 59 Suppl 1

    Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen

2000
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
    Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 11

    Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes

2002
[Perspectives for the hormonal therapy of breast cancer].
    Magyar onkologia, 2003, Volume: 47, Issue:2

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Toremifene; Triazoles

2003
Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
    Breast (Edinburgh, Scotland), 2006, Volume: 15, Issue:5

    Topics: Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Postmenopause; Raloxifene Hydrochloride; Tamoxifen

2006
Two unsuccessful clinical trials on endometriosis and a few lessons learned.
    Gynecologic and obstetric investigation, 2007, Volume: 64, Issue:1

    Topics: Adult; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endometriosis; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Needs Assessment; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Severity of Illness Index; Species Specificity; Treatment Failure

2007
Gene expression profiles in breast cancer to identify estrogen receptor target genes.
    Mini reviews in medicinal chemistry, 2008, Volume: 8, Issue:5

    Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Molecular Structure; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen

2008
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance.
    Frontiers in bioscience : a journal and virtual library, 2008, May-01, Volume: 13

    Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Male; Neoplasms; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Signal Transduction; Treatment Outcome

2008
[GPER receptor - the new player in estrogen signaling].
    Postepy biochemii, 2015, Volume: 61, Issue:1

    Topics: Animals; Autocrine Communication; Breast Neoplasms; Connective Tissue Growth Factor; Dual Specificity Phosphatase 1; Estradiol; Female; Fulvestrant; Gene Expression Regulation; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-fos; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; Tamoxifen; Transcriptional Activation

2015
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Post reproductive health, 2015, Volume: 21, Issue:3

    Topics: Animals; Breast; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrogen Antagonists; Estrogens; Estrogens, Conjugated (USP); Female; Fulvestrant; Humans; Indoles; Osteoporosis; Postmenopause; Protective Factors; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene

2015

Other Studies

78 other study(ies) available for raloxifene hydrochloride and fulvestrant

ArticleYear
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
    Journal of medicinal chemistry, 1997, May-09, Volume: 40, Issue:10

    Topics: Animals; Breast Neoplasms; Cell Division; Estrogen Antagonists; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tumor Cells, Cultured

1997
Synthesis and estrogenic activities of novel 7-thiosubstituted estratriene derivatives.
    Bioorganic & medicinal chemistry letters, 2000, Jan-17, Volume: 10, Issue:2

    Topics: Binding, Competitive; Estradiol; Estrogen Receptor Modulators; Receptors, Estrogen; Sulfhydryl Compounds; Tamoxifen

2000
Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
    Molecular carcinogenesis, 1996, Volume: 17, Issue:3

    Topics: Animals; Cell Division; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Leiomyoma; Phenotype; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Uterine Neoplasms

1996
Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels.
    Endocrinology, 1997, Volume: 138, Issue:4

    Topics: Animals; Cholesterol; Dexamethasone; Disease Models, Animal; Estradiol; Estrogen Antagonists; Estrogens; Ethinyl Estradiol; Female; Fulvestrant; Lipids; Ovariectomy; Piperidines; Progesterone; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus

1997
Estrogen receptor ligands modulate its interaction with DNA.
    The Journal of biological chemistry, 1997, Apr-25, Volume: 272, Issue:17

    Topics: DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Ethinyl Estradiol; Fulvestrant; Humans; Ligands; Piperidines; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Regulatory Sequences, Nucleic Acid; Tamoxifen; Transcription Factors

1997
FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
    Molecular endocrinology (Baltimore, Md.), 1997, Volume: 11, Issue:7

    Topics: Amino Acid Sequence; Bacterial Outer Membrane Proteins; Diethylstilbestrol; DNA Nucleotidyltransferases; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Fulvestrant; Hexestrol; HSP90 Heat-Shock Proteins; Humans; Ligands; Molecular Sequence Data; Nafoxidine; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen; Time Factors; Yeasts

1997
Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.
    The Journal of steroid biochemistry and molecular biology, 1997, Volume: 60, Issue:5-6

    Topics: Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured

1997
Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
    Cancer research, 1997, Aug-15, Volume: 57, Issue:16

    Topics: Adenocarcinoma; Alkaline Phosphatase; Benzopyrans; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Proteins; Piperidines; Propionates; Raloxifene Hydrochloride; Tamoxifen; Toremifene; Tumor Cells, Cultured

1997
Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: an in situ hybridization study.
    Endocrinology, 1997, Volume: 138, Issue:12

    Topics: Animals; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; In Situ Hybridization; Piperidines; Preoptic Area; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Progesterone; RNA, Messenger; Sensitivity and Specificity; Tamoxifen; Time Factors

1997
Positive and negative discrimination of estrogen receptor agonists and antagonists using site-specific DNA recombinase fusion proteins.
    Molecular endocrinology (Baltimore, Md.), 1998, Volume: 12, Issue:8

    Topics: Diethylstilbestrol; Dimerization; DNA Nucleotidyltransferases; Estradiol; Estrogen Antagonists; Fulvestrant; Hexestrol; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen

1998
The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.
    Cancer research, 1999, Sep-01, Volume: 59, Issue:17

    Topics: Benzopyrans; Cell Division; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Piperidines; Propionates; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

1999
Comparative analyses of mechanistic differences among antiestrogens.
    Endocrinology, 1999, Volume: 140, Issue:12

    Topics: Blood Proteins; Breast Neoplasms; Cell Division; Cinnamates; Drug Stability; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression; Humans; Protein Binding; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Stilbenes; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured

1999
Functional interactions between the estrogen receptor and DRIP205, a subunit of the heteromeric DRIP coactivator complex.
    The Journal of biological chemistry, 2000, Jul-07, Volume: 275, Issue:27

    Topics: Animals; Carrier Proteins; Cell Line; COS Cells; Estradiol; Fulvestrant; Humans; Mediator Complex; Mediator Complex Subunit 1; Mutation; Nuclear Proteins; Peptide Fragments; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Signal Transduction; Surface Plasmon Resonance; Tamoxifen; Trans-Activators; Transcription Factors; Transcriptional Activation; Transfection

2000
Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase.
    The Journal of clinical endocrinology and metabolism, 2000, Volume: 85, Issue:8

    Topics: Cells, Cultured; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Kinetics; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Raloxifene Hydrochloride; Receptors, Estrogen; Umbilical Veins

2000
Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    Cancer research, 2000, Sep-15, Volume: 60, Issue:18

    Topics: Allosteric Regulation; Amino Acid Substitution; Aspartic Acid; Binding Sites; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Glycine; Humans; Kinetics; Ligands; Mutagenesis, Site-Directed; Protein Conformation; Protein Structure, Tertiary; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured

2000
Raloxifene and estrogen inhibit neointimal thickening after balloon injury in the carotid artery of male and ovariectomized female rats.
    Journal of cardiovascular pharmacology, 2000, Volume: 36, Issue:4

    Topics: Animals; Carotid Artery Injuries; Catheterization; Cholesterol; Estradiol; Estrogen Antagonists; Ethinyl Estradiol; Female; Fulvestrant; Male; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley

2000
Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells.
    American journal of physiology. Cell physiology, 2000, Volume: 279, Issue:5

    Topics: Animals; Cells, Cultured; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Ligands; Mammary Glands, Animal; Osteoblasts; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Response Elements; Tamoxifen

2000
Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of phytoestrogens in the human breast cancer cell line MCF-7.
    Planta medica, 2001, Volume: 67, Issue:6

    Topics: Blotting, Western; Breast; Coumestrol; Diet; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Fulvestrant; Genistein; Humans; Isoflavones; Molecular Structure; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured

2001
Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells.
    The Journal of biological chemistry, 2001, Dec-14, Volume: 276, Issue:50

    Topics: Animals; Cell Line, Transformed; Cells, Cultured; CHO Cells; Cricetinae; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogens; Flavonoids; Fulvestrant; Humans; Lung; Mitogen-Activated Protein Kinases; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phosphorylation; Protein Binding; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrrolidines; Raloxifene Hydrochloride; Rats; Receptors, Estradiol; Thiophenes; Time Factors; Umbilical Veins

2001
Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7.
    The Journal of steroid biochemistry and molecular biology, 2002, Volume: 80, Issue:1

    Topics: Apoptosis; Benzhydryl Compounds; Breast Neoplasms; Cell Division; Coumestrol; DDT; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens, Non-Steroidal; Female; Fulvestrant; Humans; Molecular Structure; Phenols; Raloxifene Hydrochloride; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Surface-Active Agents; Tumor Cells, Cultured

2002
Comparative effects of testosterone propionate, oestradiol benzoate, ICI 182,780, tamoxifen and raloxifene on hypothalamic differentiation in the female rat.
    The Journal of endocrinology, 2002, Volume: 172, Issue:3

    Topics: Analysis of Variance; Animals; Animals, Newborn; Cell Differentiation; Chi-Square Distribution; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Hypothalamus; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen; Testosterone

2002
Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
    The Journal of biological chemistry, 2002, Nov-22, Volume: 277, Issue:47

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Cell Fractionation; Cell Size; Estradiol; Estrogen Antagonists; Etoposide; Fulvestrant; Genes, Reporter; HeLa Cells; Humans; Microscopy, Electron; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteins; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Transcriptional Activation

2002
Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.
    The Journal of biological chemistry, 2003, Feb-28, Volume: 278, Issue:9

    Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Glutathione Transferase; HeLa Cells; Histone Deacetylases; Humans; Luciferases; Models, Biological; Models, Molecular; Mutation; Plasmids; Precipitin Tests; Progesterone; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transfection; Tumor Cells, Cultured

2003
Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
    Molecular endocrinology (Baltimore, Md.), 2003, Volume: 17, Issue:7

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Breast Neoplasms; DNA Damage; DNA Repair; DNA-Binding Proteins; Enzyme Activation; Epithelial Cells; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Guanine; Humans; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Xeroderma Pigmentosum Group A Protein

2003
Mutation of Leu-536 in human estrogen receptor-alpha alters the coupling between ligand binding, transcription activation, and receptor conformation.
    The Journal of biological chemistry, 2003, Jul-18, Volume: 278, Issue:29

    Topics: Amino Acid Substitution; Base Sequence; Binding Sites; DNA; Estradiol; Estrogen Receptor alpha; Fulvestrant; HeLa Cells; Humans; In Vitro Techniques; Leucine; Ligands; Models, Molecular; Mutagenesis, Site-Directed; Promoter Regions, Genetic; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Transcription Factor AP-1; Transcriptional Activation; Two-Hybrid System Techniques

2003
Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus.
    Reproductive biology and endocrinology : RB&E, 2003, May-07, Volume: 1

    Topics: Animals; Cell Division; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression Regulation; Insulin-Like Growth Factor I; Ki-67 Antigen; Organ Size; Ovariectomy; Proliferating Cell Nuclear Antigen; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Receptors, Somatotropin; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus

2003
Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells.
    The Journal of endocrinology, 2003, Volume: 178, Issue:2

    Topics: Animals; Aorta; Blotting, Western; Cell Division; Cell Line; Cells, Cultured; Cyclin D1; Depression, Chemical; Estradiol; Estrogen Receptor alpha; Flow Cytometry; Fulvestrant; G1 Phase; Humans; Muscle, Smooth, Vascular; Phosphorylation; Platelet-Derived Growth Factor; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Transfection

2003
2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth.
    Gynecologic oncology, 2003, Volume: 91, Issue:2

    Topics: Antineoplastic Agents, Hormonal; Carcinosarcoma; Cell Cycle; Cell Division; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Progesterone; Raloxifene Hydrochloride; Tamoxifen; Triptorelin Pamoate; Uterine Neoplasms

2003
Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
    Journal of molecular endocrinology, 2004, Volume: 32, Issue:2

    Topics: Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pyrrolidines; Raloxifene Hydrochloride; Response Elements; Tamoxifen; Thiophenes; Transcription, Genetic; Tumor Cells, Cultured

2004
Selective estrogen receptor modulators prevent neointima formation after vascular injury.
    Molecular and cellular endocrinology, 2004, Nov-30, Volume: 227, Issue:1-2

    Topics: Animals; Aorta; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Estradiol; Estrogens; Female; Fulvestrant; Muscle, Smooth, Vascular; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen; Tunica Intima

2004
Raloxifene relaxes rat pulmonary arteries and veins: roles of gender, endothelium, and antagonism of Ca2+ influx.
    The Journal of pharmacology and experimental therapeutics, 2005, Volume: 312, Issue:3

    Topics: Animals; Calcium; Calcium Channels, L-Type; Dose-Response Relationship, Drug; Endothelium, Vascular; Estradiol; Female; Fulvestrant; Male; Pulmonary Artery; Pulmonary Veins; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Sex Characteristics; Vasodilation

2005
The putative tumor suppressor deleted in malignant brain tumors 1 is an estrogen-regulated gene in rodent and primate endometrial epithelium.
    Endocrinology, 2005, Volume: 146, Issue:3

    Topics: Agglutinins; Alu Elements; Animals; Blotting, Northern; Calcium-Binding Proteins; Cell Differentiation; Cell Line; DNA-Binding Proteins; Dose-Response Relationship, Drug; Endometrium; Epithelium; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Haplorhini; Humans; Immunohistochemistry; Luciferases; Mucins; Mucous Membrane; Oligonucleotide Array Sequence Analysis; Plasmids; Polymerase Chain Reaction; Promoter Regions, Genetic; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; RNA; Tamoxifen; Transfection; Tumor Suppressor Proteins; Up-Regulation; Uterus

2005
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-01, Volume: 11, Issue:1

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Carcinogens; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Humans; Luciferases; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Ovary; Protein Binding; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tamoxifen; Time Factors; Transcriptional Activation; Treatment Outcome; Uterus

2005
Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands.
    The Journal of endocrinology, 2005, Volume: 185, Issue:2

    Topics: Adoptive Transfer; Animals; Cell Proliferation; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Flow Cytometry; Fulvestrant; Mice; Mice, Inbred Strains; Ovariectomy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; T-Lymphocytes, Regulatory

2005
Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2005, Volume: 54, Issue:5

    Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Blotting, Northern; Cell Proliferation; Cells, Cultured; CpG Islands; DNA; Dose-Response Relationship, Drug; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Estradiol; Fulvestrant; Hippocampus; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Inflammation; Interleukin-6; L-Lactate Dehydrogenase; Lipopolysaccharides; Mice; Microglia; Nitric Oxide; Oligonucleotides; Protein Binding; Raloxifene Hydrochloride; Rats; Rats, Wistar; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors

2005
A short-incubation reporter-gene assay for high-throughput screening of estrogen receptor-alpha antagonists.
    Assay and drug development technologies, 2005, Volume: 3, Issue:4

    Topics: Animals; beta-Lactamases; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fluorescence Resonance Energy Transfer; Fulvestrant; Genetic Vectors; Raloxifene Hydrochloride; Recombinant Fusion Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors; Transcriptional Activation; Transfection

2005
Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
    Journal of the Society for Gynecologic Investigation, 2005, Volume: 12, Issue:7

    Topics: Amphiregulin; Antineoplastic Agents, Hormonal; EGF Family of Proteins; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Profiling; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured

2005
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
    Molecular and cellular endocrinology, 2005, Dec-21, Volume: 245, Issue:1-2

    Topics: Breast Neoplasms; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Mammary Glands, Human; Mutation; Oligonucleotide Array Sequence Analysis; Protein Binding; Raloxifene Hydrochloride; Receptor Cross-Talk; Response Elements; Signal Transduction; Tamoxifen; Transcription Factors

2005
Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep.
    American journal of physiology. Heart and circulatory physiology, 2006, Volume: 291, Issue:3

    Topics: Animals; Coronary Vessels; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression Regulation; Hemodynamics; Ovariectomy; Raloxifene Hydrochloride; Regional Blood Flow; RNA, Messenger; Sheep; Stroke Volume; Uterus; Vasodilation

2006
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-01, Volume: 12, Issue:7 Pt 1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Quinazolines; Raloxifene Hydrochloride; RNA, Messenger; Structure-Activity Relationship; Transplantation, Heterologous; Trastuzumab; Xenograft Model Antitumor Assays

2006
AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines.
    BMC cancer, 2006, May-02, Volume: 6

    Topics: Acetyltransferases; Alleles; Breast Neoplasms; Cell Line, Tumor; Cloning, Molecular; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Receptor Coactivator 3; Oncogene Proteins; Peptides; Polymerase Chain Reaction; Pyrrolidines; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Sequence Analysis, DNA; Tamoxifen; Thiophenes; Trans-Activators

2006
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
    Cancer, 2006, Jun-15, Volume: 106, Issue:12

    Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Microarray Analysis; Neoplasm Staging; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Urinary Bladder Neoplasms

2006
Characterisation of the relaxant response to raloxifene in porcine coronary arteries.
    European journal of pharmacology, 2006, Sep-18, Volume: 545, Issue:2-3

    Topics: Animals; Calcium; Calcium Channels; Coronary Vessels; Estradiol; Fulvestrant; Imidazoles; In Vitro Techniques; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Swine; Vasodilation

2006
Raloxifene elicits combined rapid vasorelaxation and long-term anti-inflammatory actions in rat aorta.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Aorta, Thoracic; Blotting, Western; Cell Survival; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; In Vitro Techniques; Isometric Contraction; Kinetics; Lipopolysaccharides; Muscle Relaxation; Muscle, Smooth, Vascular; Nitrites; Ovariectomy; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators

2006
Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1.
    BMC cardiovascular disorders, 2006, Oct-09, Volume: 6

    Topics: Cells, Cultured; Down-Regulation; Endothelial Cells; Estradiol; Estrogen Receptor alpha; Ethinyl Estradiol; Fulvestrant; Humans; Lipoproteins; Raloxifene Hydrochloride; RNA, Messenger; Selective Estrogen Receptor Modulators

2006
Effects of raloxifene on caveolin-1 mRNA and protein expressions in vascular smooth muscle cells.
    Acta biochimica et biophysica Sinica, 2006, Volume: 38, Issue:11

    Topics: Animals; Aorta; Cardiotonic Agents; Caveolin 1; Cells, Cultured; Estradiol; Female; Fulvestrant; Gene Expression Regulation; Myocytes, Smooth Muscle; Raloxifene Hydrochloride; Rats; Rats, Wistar; Receptors, Estrogen; RNA, Messenger; Selective Estrogen Receptor Modulators

2006
Endothelium-independent relaxation to raloxifene in porcine coronary artery.
    European journal of pharmacology, 2007, Jan-26, Volume: 555, Issue:2-3

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Calcium Channel Blockers; Calcium Channels; Calcium Chloride; Coronary Vessels; Endothelin-1; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Fulvestrant; In Vitro Techniques; Peptides; Potassium Channel Blockers; Potassium Channels, Calcium-Activated; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Serotonin; Swine; Tetraethylammonium; Vasoconstrictor Agents; Vasodilation

2007
Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.
    International journal of oncology, 2007, Volume: 30, Issue:2

    Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Prohibitins; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen; Uterine Neoplasms

2007
Raloxifene and ICI182,780 increase estrogen receptor-alpha association with a nuclear compartment via overlapping sets of hydrophobic amino acids in activation function 2 helix 12.
    Molecular endocrinology (Baltimore, Md.), 2007, Volume: 21, Issue:4

    Topics: Amino Acid Motifs; Amino Acid Sequence; Amino Acid Substitution; Amino Acids; Cell Nucleus; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Humans; Leucine; Molecular Sequence Data; Mutation; Protein Structure, Secondary; Raloxifene Hydrochloride; Solubility; Transcription, Genetic; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins

2007
Effect of genistein and raloxifene on vascular dependent platelet aggregation.
    Molecular and cellular endocrinology, 2007, Mar-15, Volume: 267, Issue:1-2

    Topics: Adenosine Diphosphate; Animals; Antineoplastic Agents; Aorta; Eicosanoids; Estradiol; Female; Fulvestrant; Genistein; In Vitro Techniques; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Ovariectomy; Platelet Aggregation; Platelet Aggregation Inhibitors; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators

2007
Raloxifene inhibits transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes.
    European journal of pharmacology, 2007, Jun-01, Volume: 563, Issue:1-3

    Topics: Action Potentials; Cells, Cultured; Delayed Rectifier Potassium Channels; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Fulvestrant; Heart Atria; Humans; Middle Aged; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium; Potassium Channel Blockers; Potassium Channels; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Time Factors

2007
Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes.
    Maturitas, 2007, May-20, Volume: 57, Issue:1

    Topics: Breast Neoplasms; Carcinoma; Down-Regulation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured; Up-Regulation

2007
Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
    British journal of pharmacology, 2007, Volume: 151, Issue:3

    Topics: Animals; Apoptosis; Bone Resorption; Cattle; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Dexamethasone; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Lipopolysaccharide Receptors; Macrophage Colony-Stimulating Factor; Monocytes; Osteoclasts; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Tumor Necrosis Factor-alpha

2007
Raloxifene acutely reduces glutamate-induced intracellular calcium increase in cultured rat cortical neurons via inhibition of high-voltage-activated calcium current.
    Neuroscience, 2007, Jun-29, Volume: 147, Issue:2

    Topics: Animals; Animals, Newborn; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Signaling; Cell Membrane; Cells, Cultured; Cerebral Cortex; Diagnostic Imaging; Electrophysiology; Endoplasmic Reticulum; Estradiol; Estrogen Antagonists; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Fulvestrant; Glutamic Acid; N-Methylaspartate; Neurons; Patch-Clamp Techniques; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Thapsigargin

2007
Therapeutic concentrations of raloxifene augment nitric oxide-dependent coronary artery dilatation in vitro.
    British journal of pharmacology, 2007, Volume: 152, Issue:2

    Topics: Animals; Bradykinin; Coronary Vessels; Estradiol; Estrogen Antagonists; Fulvestrant; In Vitro Techniques; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Synthase Type III; Raloxifene Hydrochloride; Swine; Vasodilation; Vasodilator Agents

2007
Mechanism of collagen biosynthesis up-regulation in cultured leiomyoma cells.
    Folia histochemica et cytobiologica, 2007, Volume: 45 Suppl 1

    Topics: Blotting, Western; Cells, Cultured; Collagen; Dipeptidases; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Estradiol; Female; Fulvestrant; Humans; Leiomyoma; Middle Aged; Myometrium; Raloxifene Hydrochloride; Tamoxifen; Up-Regulation

2007
Genomic deletion of estrogen receptors ERalpha and ERbeta does not alter estrogen-mediated inhibition of Ca2+ influx and contraction in murine cardiomyocytes.
    American journal of physiology. Heart and circulatory physiology, 2008, Volume: 294, Issue:6

    Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Signaling; Cell Size; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Fulvestrant; Genomics; Membrane Potentials; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Contraction; Myocytes, Cardiac; Patch-Clamp Techniques; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators

2008
Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway.
    European journal of pharmacology, 2008, Jul-28, Volume: 589, Issue:1-3

    Topics: Animals; Apoptosis; Cattle; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Activation; Estradiol; Estrogen Antagonists; Flavonoids; Fulvestrant; Hydrogen Peroxide; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Oxidants; Oxidative Stress; Phosphorylation; Protein Kinase Inhibitors; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Thiophenes

2008
Comparative effects of estradiol, methyl-piperidino-pyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus.
    Journal of molecular endocrinology, 2008, Volume: 41, Issue:4

    Topics: Animals; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression; Mice; Oligonucleotide Array Sequence Analysis; Ovariectomy; Piperidines; Pyrazoles; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Uterus

2008
Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Nov-17, Volume: 106, Issue:46

    Topics: Animals; Antineoplastic Agents, Hormonal; Disease Models, Animal; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mice; Mice, Transgenic; Papillomavirus Infections; Raloxifene Hydrochloride; Uterine Cervical Neoplasms

2009
Effect of selective estrogen receptor modulator/raloxifene analogue on proliferation and collagen metabolism of tendon fibroblast.
    Connective tissue research, 2010, Volume: 51, Issue:3

    Topics: Achilles Tendon; Animals; Bromodeoxyuridine; Cell Proliferation; Cell Survival; Cells, Cultured; Collagen Type I; Collagen Type III; Elastin; Estradiol; Estrogen Antagonists; Extracellular Matrix; Female; Fibroblasts; Fulvestrant; Matrix Metalloproteinase 13; Pyrrolidines; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Tetrazolium Salts; Thiophenes

2010
Therapeutically relevant concentrations of raloxifene dilate pressurized rat resistance arteries via calcium-dependent endothelial nitric oxide synthase activation.
    Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:5

    Topics: Androstadienes; Animals; Apamin; Blood Pressure; Calcium Signaling; Charybdotoxin; Chromones; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; In Vitro Techniques; Male; Mesenteric Arteries; Morpholines; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Ovariectomy; Phosphorylation; Potassium Channel Blockers; Protein Kinase Inhibitors; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Sex Factors; Time Factors; Vascular Resistance; Vasodilation; Vasodilator Agents; Wortmannin

2010
Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta.
    International journal of oncology, 2010, Volume: 36, Issue:5

    Topics: Carcinoma; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Phosphorylation; Raloxifene Hydrochloride; RNA, Small Interfering; Signal Transduction; Tamoxifen; Thyroid Neoplasms

2010
High content imaging-based assay to classify estrogen receptor-α ligands based on defined mechanistic outcomes.
    Gene, 2011, May-15, Volume: 477, Issue:1-2

    Topics: Benzhydryl Compounds; Blotting, Western; Cell Line, Tumor; Cluster Analysis; Endocrine Disruptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Green Fluorescent Proteins; HeLa Cells; Humans; Microscopy, Fluorescence; Phenols; Principal Component Analysis; Promoter Regions, Genetic; Raloxifene Hydrochloride; Reproducibility of Results; Tamoxifen

2011
Specific transcriptional response of four blockers of estrogen receptors on estradiol-modulated genes in the mouse mammary gland.
    Breast cancer research and treatment, 2012, Volume: 134, Issue:2

    Topics: Animals; Cluster Analysis; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Genes; Genes, Neoplasm; Mammary Glands, Animal; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transcriptome

2012
Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
    Hormones & cancer, 2013, Volume: 4, Issue:1

    Topics: Apoptosis; Carcinoma, Transitional Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Immediate-Early Proteins; MCF-7 Cells; Poly(ADP-ribose) Polymerases; Raloxifene Hydrochloride; S-Phase Kinase-Associated Proteins; Tamoxifen; Tumor Suppressor Proteins; Urinary Bladder Neoplasms

2013
Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes.
    Molecular pharmacology, 2013, Volume: 83, Issue:5

    Topics: Cell Line, Tumor; DNA; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression; HeLa Cells; Hep G2 Cells; Humans; Indoles; Ligands; Mutation; Promoter Regions, Genetic; Protein Multimerization; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic; Transcriptional Activation

2013
Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells.
    Pharmacological research, 2014, Volume: 79

    Topics: Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Curcumin; Estradiol; Estrogen Receptor beta; Estrogen Receptor Modulators; Fulvestrant; Genistein; Humans; Male; Prostatic Neoplasms; Raloxifene Hydrochloride; Tamoxifen

2014
The estrogen receptor antagonist ICI 182,780 can act both as an agonist and an inverse agonist when estrogen receptor α AF-2 is modified.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Jan-21, Volume: 111, Issue:3

    Topics: Adipose Tissue; Animals; Bone and Bones; Bone Marrow Cells; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Insulin-Like Growth Factor I; Ligands; Mice; Mutation; Organ Size; Protein Structure, Tertiary; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tetrahydronaphthalenes; Thymus Gland; Tissue Distribution; Tomography, X-Ray Computed; Uterus; X-Ray Microtomography

2014
Raloxifene suppresses experimental autoimmune encephalomyelitis and NF-κB-dependent CCL20 expression in reactive astrocytes.
    PloS one, 2014, Volume: 9, Issue:4

    Topics: Animals; Astrocytes; Cell Movement; Cells, Cultured; Chemokine CCL20; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Estradiol; Female; Fulvestrant; Gene Expression Regulation; Mice; Mice, Inbred C57BL; Multiple Sclerosis; NF-kappa B; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Th17 Cells

2014
Selective estrogen-receptor modulators suppress microglial activation and neuronal cell death via an estrogen receptor-dependent pathway.
    The Journal of steroid biochemistry and molecular biology, 2015, Volume: 145

    Topics: Animals; Cell Death; Cell Line, Tumor; Cell Survival; Culture Media, Conditioned; Enzyme-Linked Immunosorbent Assay; Estradiol; Female; Fulvestrant; Inflammation; Male; Microglia; Neurons; Plasmids; Raloxifene Hydrochloride; Rats; Rats, Wistar; Receptors, Estrogen; Response Elements; Selective Estrogen Receptor Modulators; Tamoxifen

2015
[Fluid shear stress and raloxifene stimulates the proliferation of osteoblast through regulating the expresstion of β-catenin and estrogen receptor α].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2014, Volume: 45, Issue:6

    Topics: 3T3 Cells; Animals; beta Catenin; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Fulvestrant; Mice; Osteoblasts; Raloxifene Hydrochloride; RNA, Messenger; Signal Transduction; Stress, Mechanical

2014
Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis.
    Journal of pharmacological sciences, 2015, Volume: 128, Issue:3

    Topics: Catalysis; Cytosol; Estradiol; Fulvestrant; Hep G2 Cells; Humans; MCF-7 Cells; Raloxifene Hydrochloride; Sulfates; Sulfotransferases; Tamoxifen

2015
Improved specificity of hippocampal memory trace labeling.
    Hippocampus, 2016, Volume: 26, Issue:6

    Topics: Animals; Bacterial Proteins; Cell Count; Channelrhodopsins; Conditioning, Psychological; Estradiol; Fear; Fulvestrant; Hippocampus; Immunohistochemistry; Luminescent Proteins; Memory; Mice, Transgenic; Microscopy, Confocal; Models, Animal; Neurons; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Untranslated; Selective Estrogen Receptor Modulators; Tamoxifen

2016
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
    Oncology reports, 2016, Volume: 36, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Leupeptins; MCF-7 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen

2016
Daidzein increases OPG/RANKL ratio and suppresses IL-6 in MG-63 osteoblast cells.
    International immunopharmacology, 2016, Volume: 40

    Topics: Cell Line; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Fulvestrant; Humans; Interleukin-6; Isoflavones; Nuclear Receptor Coactivator 1; Osteoblasts; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; RNA, Small Interfering

2016
Clinically used selective estrogen receptor modulators affect different steps of macrophage-specific reverse cholesterol transport.
    Scientific reports, 2016, 09-07, Volume: 6

    Topics: Acetyl-CoA C-Acetyltransferase; Animals; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G; Biological Transport; Cholesterol; Cholesterol Esters; Diet, Western; Esterification; Estradiol; Feces; Fulvestrant; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; THP-1 Cells; Toremifene

2016
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
    eLife, 2018, 11-29, Volume: 7

    Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indoles; Ligands; MCF-7 Cells; Mutant Proteins; Mutation; Piperazines; Protein Binding; Protein Domains; Protein Structure, Secondary; Pyridines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen

2018